AbbVie: agreement to acquire Capstan

Published: 2025-06-30 10:15:47 ET ABBV

Published on 06/30/2025 at 10:15

AbbVie announces that it has entered into a definitive agreement to acquire Capstan Therapeutics, including CPTX2309, currently in Phase 1 development for the treatment of B-cell-mediated autoimmune diseases.More broadly, it will acquire its proprietary targeted lipid nanoparticle technology platform, designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types in vivo.AbbVie and Capstan aim to transform care for people with autoimmune diseases by developing treatments that have the potential to reset the immune system, it said.AbbVie will pay up to $2.1bn in cash upon the transaction's closing, subject to certain customary adjustments. The transaction is subject to customary closing conditions, including regulatory approvals.Copyright (c) 2025 CercleFinance.com - All rights reserved.